Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19
Abstract
Introduction: Autoantibodies neutralizing type I interferon (AAN-I-IFN) have been found in at least 10-15% of critical COVID-19 pneumonia cases in various studies across North and Latin America, Oceania, Europe, and Asia. We sought to analyze the prevalence of AAN-I-IFN and describe the demographic, clinical, and laboratory characteristics in a Moroccan cohort of patients with life-threatening COVID-19. Methods: We performed a cross-sectional and multicenter study of patients hospitalized in different university hospitals and clinical centers in Casablanca between November 2020 and December 2021. Results: Our cohort included 195 patients with proven SARS-CoV-2 infection, 164 (84.1%) of whom developed severe or critical COVID-19 disease requiring hospitalization, and 31 (15.9%) patients developed mild or moderate disease. Patients with moderate or mild COVID-19 did not exhibit detectable levels of AAN-I-IFNs. Among the 20 patients with AAN-I-IFN, most were men (n=16, 80%), and age ranged from 19 to 101 years. 13 (65%) patients with severe COVID-19 and 7 (35%) with critical COVID-19 had AAN-I-IFNs. Twelve patients (60%) had autoantibodies (auto-Abs) neutralizing both high and low concentrations of IFN-α2 and/or IFN-ω, five (25%) had auto-Abs neutralizing only low concentrations of IFN-α2 or IFN-ω, two (10%) had auto-Abs neutralizing IFN-β (1ng/mL) only, and one (5%) had auto-Abs neutralizing high and low concentrations of IFN-α2 and IFN-ω, as well as IFN-β at 1ng/mL, but none neutralized IFN-β at 10 ng/mL. Conclusion: Overall, AAN-I-IFNs were detected in 20/195 (10.3%) of Moroccan patients with life-threatening COVID-19 and in 20/164 (12.2%) patients with severe or critical disease, whereas none were detected in patients with mild or moderate COVID-19.
Related
- Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026
- Cervicovaginal Neutralizing Antibodies to Herpes Simplex Virus (HSV) in Women Seropositive for HSV Types 1 and 2
- The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages
- Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer
- An adenovirus-based mucosal vaccine induces cross-neutralizing antibodies and protects against lethal H5N1 infection in ferrets
BibTeX
@article{kholaiq2026autoantibodies,
title = {{Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19}},
author = {Halima Kholaiq and Adrian Gervais and Paul Bastard and Hind Ouair and Lucy Bizien and Amyrath Géraldo and Fatima Ailal and Ibtihal Benhsaien and Assiya El Kettani and Ouissal Aissaoui and Naima Amenzoui and Chafik El Kettani El Hamidi and Boubaker Charra and Maha Soussi Abdallaoui and Rachid Al Harrar and Lahoucine Barrou and Mohamed Benghanem Gharbi and Moulay Hicham Afif and Qian Zhang and Laurent Abel and Aurélie Cobat and Anne Puel and Emmanuelle Jouanguy and Jean-Laurent Casanova and Ahmed Aziz Bousfiha and Jalila El Bakkouri},
journal = {Frontiers in Immunology},
year = {2026},
month = jul,
doi = {10.3389/fimmu.2026.1870598},
url = {https://hal.science/hal-05863732v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19
AU - Halima Kholaiq
AU - Adrian Gervais
AU - Paul Bastard
AU - Hind Ouair
AU - Lucy Bizien
AU - Amyrath Géraldo
AU - Fatima Ailal
AU - Ibtihal Benhsaien
AU - Assiya El Kettani
AU - Ouissal Aissaoui
AU - Naima Amenzoui
AU - Chafik El Kettani El Hamidi
AU - Boubaker Charra
AU - Maha Soussi Abdallaoui
AU - Rachid Al Harrar
AU - Lahoucine Barrou
AU - Mohamed Benghanem Gharbi
AU - Moulay Hicham Afif
AU - Qian Zhang
AU - Laurent Abel
AU - Aurélie Cobat
AU - Anne Puel
AU - Emmanuelle Jouanguy
AU - Jean-Laurent Casanova
AU - Ahmed Aziz Bousfiha
AU - Jalila El Bakkouri
PY - 2026
DA - 2026/07/14
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1870598
UR - https://hal.science/hal-05863732v1
AB - Introduction: Autoantibodies neutralizing type I interferon (AAN-I-IFN) have been found in at least 10-15% of critical COVID-19 pneumonia cases in various studies across North and Latin America, Oceania, Europe, and Asia. We sought to analyze the prevalence of AAN-I-IFN and describe the demographic, clinical, and laboratory characteristics in a Moroccan cohort of patients with life-threatening COVID-19. Methods: We performed a cross-sectional and multicenter study of patients hospitalized in different university hospitals and clinical centers in Casablanca between November 2020 and December 2021. Results: Our cohort included 195 patients with proven SARS-CoV-2 infection, 164 (84.1%) of whom developed severe or critical COVID-19 disease requiring hospitalization, and 31 (15.9%) patients developed mild or moderate disease. Patients with moderate or mild COVID-19 did not exhibit detectable levels of AAN-I-IFNs. Among the 20 patients with AAN-I-IFN, most were men (n=16, 80%), and age ranged from 19 to 101 years. 13 (65%) patients with severe COVID-19 and 7 (35%) with critical COVID-19 had AAN-I-IFNs. Twelve patients (60%) had autoantibodies (auto-Abs) neutralizing both high and low concentrations of IFN-α2 and/or IFN-ω, five (25%) had auto-Abs neutralizing only low concentrations of IFN-α2 or IFN-ω, two (10%) had auto-Abs neutralizing IFN-β (1ng/mL) only, and one (5%) had auto-Abs neutralizing high and low concentrations of IFN-α2 and IFN-ω, as well as IFN-β at 1ng/mL, but none neutralized IFN-β at 10 ng/mL. Conclusion: Overall, AAN-I-IFNs were detected in 20/195 (10.3%) of Moroccan patients with life-threatening COVID-19 and in 20/164 (12.2%) patients with severe or critical disease, whereas none were detected in patients with mild or moderate COVID-19.
SN - 1664-3224
SN - 1664-3224
ER -